PMID- 35448190
OWN - NLM
STAT- MEDLINE
DCOM- 20220425
LR  - 20240102
IS  - 1718-7729 (Electronic)
IS  - 1198-0052 (Print)
IS  - 1198-0052 (Linking)
VI  - 29
IP  - 4
DP  - 2022 Apr 11
TI  - 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage 
      Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving 
      Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal 
      Irinotecan: Preliminary Results from Clinical Practice.
PG  - 2644-2649
LID - 10.3390/curroncol29040216 [doi]
AB  - Salvage chemotherapy for patients with unresectable pancreatic cancer (UR-PC) who 
      have been treated with gemcitabine and nab-paclitaxel (GnP), and 5-fluorouracil 
      (5-FU)/l-leucovorin (LV) plus nanoliposomal irinotecan (nal-IRI), has not been 
      fully established. We retrospectively reviewed data from 17 patients with UR-PC 
      who initiated 5-FU/l-LV plus oxaliplatin (FOLFOX) as salvage chemotherapy at our 
      hospital between June 2020 and August 2021, after treatment with GnP and 5-FU/LV 
      plus nal-IRI. The primary endpoint was tumor response. The secondary endpoints 
      were progression-free survival (PFS) and adverse events (AEs). The response and 
      disease control rates were 5.9% (1/17) and 17.6% (3/17), respectively. The median 
      PFS was 1.8 months (range: 0.4-5.2 months). Eight patients (47.1%) experienced 
      grade 3 nonhematologic AEs, while none experienced grade 3 hematologic AEs. Two 
      patients with controlled disease had homologous recombination deficiency 
      (HRD)-associated gene mutations in cancer panel testing. The FOLFOX regimen 
      benefit for UR-PC patients treated with GnP and 5-FU/LV plus nal-IRI may be 
      limited to patients with HRD-associated gene mutations.
FAU - Yamai, Takuo
AU  - Yamai T
AUID- ORCID: 0000-0002-5448-4763
AD  - Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer 
      Institute, 3-1-69 Otemae, Chou-ku, Osaka 541-8567, Japan.
FAU - Ikezawa, Kenji
AU  - Ikezawa K
AUID- ORCID: 0000-0001-7517-8960
AD  - Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer 
      Institute, 3-1-69 Otemae, Chou-ku, Osaka 541-8567, Japan.
FAU - Kawamoto, Yasuharu
AU  - Kawamoto Y
AD  - Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer 
      Institute, 3-1-69 Otemae, Chou-ku, Osaka 541-8567, Japan.
FAU - Hirao, Takeru
AU  - Hirao T
AD  - Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer 
      Institute, 3-1-69 Otemae, Chou-ku, Osaka 541-8567, Japan.
FAU - Higashi, Sena
AU  - Higashi S
AD  - Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer 
      Institute, 3-1-69 Otemae, Chou-ku, Osaka 541-8567, Japan.
FAU - Daiku, Kazuma
AU  - Daiku K
AD  - Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer 
      Institute, 3-1-69 Otemae, Chou-ku, Osaka 541-8567, Japan.
FAU - Maeda, Shingo
AU  - Maeda S
AD  - Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer 
      Institute, 3-1-69 Otemae, Chou-ku, Osaka 541-8567, Japan.
FAU - Abe, Yutaro
AU  - Abe Y
AD  - Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer 
      Institute, 3-1-69 Otemae, Chou-ku, Osaka 541-8567, Japan.
FAU - Urabe, Makiko
AU  - Urabe M
AD  - Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer 
      Institute, 3-1-69 Otemae, Chou-ku, Osaka 541-8567, Japan.
FAU - Kai, Yugo
AU  - Kai Y
AD  - Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer 
      Institute, 3-1-69 Otemae, Chou-ku, Osaka 541-8567, Japan.
FAU - Takada, Ryoji
AU  - Takada R
AUID- ORCID: 0000-0002-6568-8091
AD  - Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer 
      Institute, 3-1-69 Otemae, Chou-ku, Osaka 541-8567, Japan.
FAU - Nakabori, Tasuku
AU  - Nakabori T
AD  - Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer 
      Institute, 3-1-69 Otemae, Chou-ku, Osaka 541-8567, Japan.
FAU - Uehara, Hiroyuki
AU  - Uehara H
AD  - Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer 
      Institute, 3-1-69 Otemae, Chou-ku, Osaka 541-8567, Japan.
FAU - Ohkawa, Kazuyoshi
AU  - Ohkawa K
AD  - Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer 
      Institute, 3-1-69 Otemae, Chou-ku, Osaka 541-8567, Japan.
LA  - eng
PT  - Journal Article
DEP - 20220411
PL  - Switzerland
TA  - Curr Oncol
JT  - Current oncology (Toronto, Ont.)
JID - 9502503
RN  - 0 (130-nm albumin-bound paclitaxel)
RN  - 0 (Albumins)
RN  - 04ZR38536J (Oxaliplatin)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 7673326042 (Irinotecan)
RN  - P88XT4IS4D (Paclitaxel)
RN  - Q573I9DVLP (Leucovorin)
RN  - U3P01618RT (Fluorouracil)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Albumins
MH  - *Antineoplastic Combined Chemotherapy Protocols
MH  - Deoxycytidine/analogs & derivatives
MH  - Fluorouracil/therapeutic use
MH  - Humans
MH  - Irinotecan/pharmacology/therapeutic use
MH  - Leucovorin/therapeutic use
MH  - Oxaliplatin/pharmacology/therapeutic use
MH  - Paclitaxel
MH  - *Pancreatic Neoplasms
MH  - Retrospective Studies
MH  - Gemcitabine
PMC - PMC9026505
OTO - NOTNLM
OT  - FOLFOX
OT  - chemotherapy
OT  - pancreatic cancer
COIS- The authors declare no conflict of interest.
EDAT- 2022/04/22 06:00
MHDA- 2022/04/26 06:00
PMCR- 2022/04/11
CRDT- 2022/04/21 20:19
PHST- 2022/02/14 00:00 [received]
PHST- 2022/03/30 00:00 [revised]
PHST- 2022/04/08 00:00 [accepted]
PHST- 2022/04/21 20:19 [entrez]
PHST- 2022/04/22 06:00 [pubmed]
PHST- 2022/04/26 06:00 [medline]
PHST- 2022/04/11 00:00 [pmc-release]
AID - curroncol29040216 [pii]
AID - curroncol-29-00216 [pii]
AID - 10.3390/curroncol29040216 [doi]
PST - epublish
SO  - Curr Oncol. 2022 Apr 11;29(4):2644-2649. doi: 10.3390/curroncol29040216.